Cargando…

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

Detalles Bibliográficos
Autores principales:	Yan, Ningning, Huang, Siyuan, Li, Linlin, Guo, Qianqian, Geng, Di, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415062/ https://www.ncbi.nlm.nih.gov/pubmed/37576810 http://dx.doi.org/10.3389/fphar.2023.1256801

Ejemplares similares

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2022)

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
por: Geng, Di, et al.
Publicado: (2022)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
por: Li, Linlin, et al.
Publicado: (2023)

LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN
por: Zhang, Huixian, et al.
Publicado: (2021)

Retraction Note: LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN
por: Zhang, Huixian, et al.
Publicado: (2022)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
por: Cao, Jun, et al.
Publicado: (2022)

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report
por: Wang, Jinjing, et al.
Publicado: (2021)

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report
por: Wu, Xiaokang, et al.
Publicado: (2021)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report
por: Yang, Tao, et al.
Publicado: (2018)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
por: Nie, Xin, et al.
Publicado: (2023)

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
por: Liu, Junfang, et al.
Publicado: (2022)

Schimke Immuno-osseous Dysplasia: A Case Report
por: Babaei, Amir Hossein, et al.
Publicado: (2019)

Schimke immuno-osseous dysplasia. A case report in Colombia
por: Orozco, Rafael Adrián Pacheco, et al.
Publicado: (2023)

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis
por: Guo, Sanxing, et al.
Publicado: (2020)

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
por: Shu, Yun, et al.
Publicado: (2020)

Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
por: Lin, YunYu, et al.
Publicado: (2022)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
por: Zhu, You‐cai, et al.
Publicado: (2017)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Verrucous Granular Parakeratosis on the Groin: A Case Report
por: Li, Huixian, et al.
Publicado: (2023)

Seminoma arising in splenogonadal fusion: a case report and literature review
por: Shen, Donglai, et al.
Publicado: (2023)

Novel ALK mutation with durable response to brigatinib—a case report
por: Latif, Hira, et al.
Publicado: (2020)

HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE
por: Ku, Dennis Tak-Loi, et al.
Publicado: (2020)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

LGG-56. INFANTILE HEMISPHERIC BRAIN TUMOR WITH A GOPC-ROS1 FUSION GENE: A CASE REPORT
por: Taniguchi, Rieko, et al.
Publicado: (2020)

Isolated ovarian tuberculosis in an Immuno- competent woman in the post partum period: case report
por: Gudu, Wondimu
Publicado: (2018)

Candida lusitaniae Breakthrough Fungemia in an Immuno-Compromised Adolescent: Case Report and Review of the Literature
por: Apsemidou, Athanasia, et al.
Publicado: (2020)

Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review
por: Liu, Lan, et al.
Publicado: (2017)

A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report
por: Li, Juming, et al.
Publicado: (2020)

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
por: Shu, Yun, et al.
Publicado: (2023)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Podocytic infolding in Schimke immuno-osseous dysplasia with novel SMARCAL1 mutations: a case report
por: Xiong, Shiqiu, et al.
Publicado: (2020)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v3vs35tokgui0v18k78j7qguqk